{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:32:48Z","timestamp":1792672368897,"version":"4.5.0"},"reference-count":50,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,8,28]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Patients with systemic lupus erythematosus (SLE) commonly develop lupus nephritis (LN), the most frequent severe organ manifestation of this systemic autoimmune disease. Using serum and urine samples from a phase 2 trial in LN, we investigated that how the LN metabolome is modulated in response to type I interferon receptor blockade with anifrolumab, an approved treatment for moderate to severe SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients in TULIP-LN (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02547922\">NCT02547922<\/jats:ext-link>\n                      ) received standard therapy plus intravenous anifrolumab or placebo. Untargeted metabolomics analysis was performed on serum and urine samples from 128 and 119 patients, respectively. Metabolites impacted by anifrolumab and their associations with clinical, serological and kidney measures of LN disease activity were examined. An in vitro model was used to validate the impact of anifrolumab on metabolite-induced inflammation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In serum, indoxyl sulfate (IS) and cytosine were the metabolites most modulated by anifrolumab, while baseline levels correlated with measures of kidney damage. In urine, uracil and cytosine were the most modulated by anifrolumab and levels of these metabolites were associated with serological markers of disease activity. Anifrolumab reduced markers of vascular dysfunction and inflammation upregulated by IS in in vitro models. Baseline urine uracil levels predicted response to anifrolumab intensive regimen at Week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings establish a connection between type I interferon signalling, pyrimidine metabolism and uremic toxins in patients with LN and support the evaluation of urine uracil as a potential biomarker of response to anifrolumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005932","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:35:23Z","timestamp":1759732523000},"page":"e005932","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02547922","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02547922","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05138133","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Patrick G","family":"Gavin","sequence":"first","affiliation":[{"name":"Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik L","family":"Allman","sequence":"additional","affiliation":[{"name":"Dynamic Omics, Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":false,"given":"David","family":"Jayne","sequence":"additional","affiliation":[{"name":"University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n M\u00e9dica de Investigaci\u00f3n, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[{"name":"French National Reference Center for SLE, H\u00f4pital La Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Di Poto","sequence":"additional","affiliation":[{"name":"Dynamic Omics, Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Tian","sequence":"additional","affiliation":[{"name":"Dynamic Omics, Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Hess","sequence":"additional","affiliation":[{"name":"Dynamic Omics, Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Csomor","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip Z","family":"Brohawn","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Muthas","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Platt","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Anzillotti","sequence":"additional","affiliation":[{"name":"Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Stone","sequence":"additional","affiliation":[{"name":"Bioscience Renal, Early Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Seth","sequence":"additional","affiliation":[{"name":"Bioscience Renal, Early Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Woollard","sequence":"additional","affiliation":[{"name":"Bioscience Renal, Early Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Al-Mossawi","sequence":"additional","affiliation":[{"name":"Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Lindholm","sequence":"additional","affiliation":[{"name":"Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"key":"2026010700550926000_11.4.e005932.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00398-2"},{"key":"2026010700550926000_11.4.e005932.2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026010700550926000_11.4.e005932.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.10.014"},{"key":"2026010700550926000_11.4.e005932.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210391"},{"key":"2026010700550926000_11.4.e005932.5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ekir.2024.10.013","article-title":"Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities","volume":"10","author":"Tumlin","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026010700550926000_11.4.e005932.6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","article-title":"Lupus nephritis-related chronic kidney disease","volume":"20","author":"Lichtnekert","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2026010700550926000_11.4.e005932.7","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.686249","article-title":"Uremic Toxins: An Alarming Danger Concerning the Cardiovascular System","volume":"12","author":"Falconi","year":"2021","journal-title":"Front Physiol"},{"key":"2026010700550926000_11.4.e005932.8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02660221"},{"key":"2026010700550926000_11.4.e005932.9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5606\/ArchRheumatol.2017.6127","article-title":"A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis","volume":"33","author":"Wang","year":"2018","journal-title":"Arch Rheumatol"},{"key":"2026010700550926000_11.4.e005932.10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1159\/000517852","article-title":"Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review","volume":"52","author":"Radin","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026010700550926000_11.4.e005932.11","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000747","article-title":"Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis","volume":"10","author":"Akhgar","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2026010700550926000_11.4.e005932.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.08.021"},{"key":"2026010700550926000_11.4.e005932.13","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41467-019-09329-0","article-title":"Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan","volume":"10","author":"Chen","year":"2019","journal-title":"Nat Commun"},{"key":"2026010700550926000_11.4.e005932.14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/art.43020","article-title":"Urinary Biomarkers: Toward a Liquid Biopsy for Lupus Nephritis","volume":"77","author":"Fava","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026010700550926000_11.4.e005932.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00488-2"},{"key":"2026010700550926000_11.4.e005932.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.30"},{"key":"2026010700550926000_11.4.e005932.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.806560","article-title":"The Role of Immunometabolism in the Pathogenesis of Systemic Lupus Erythematosus","volume":"12","author":"Robinson","year":"2021","journal-title":"Front Immunol"},{"key":"2026010700550926000_11.4.e005932.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037210","article-title":"Metabolic Disturbances Associated with Systemic Lupus Erythematosus","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS ONE"},{"key":"2026010700550926000_11.4.e005932.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159384","article-title":"Metabolic Profiling of Systemic Lupus Erythematosus and Comparison with Primary Sj\u00f6gren\u2019s Syndrome and Systemic Sclerosis","volume":"11","author":"Bengtsson","year":"2016","journal-title":"PLoS One"},{"key":"2026010700550926000_11.4.e005932.20","doi-asserted-by":"crossref","first-page":"109057","DOI":"10.1016\/j.clim.2022.109057","article-title":"Integration of metabolomics and lipidomics reveals serum biomarkers for systemic lupus erythematosus with different organs involvement","volume":"241","author":"Zhang","year":"2022","journal-title":"Clin Immunol"},{"key":"2026010700550926000_11.4.e005932.21","doi-asserted-by":"crossref","DOI":"10.1186\/ar3530","article-title":"Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis","volume":"13","author":"Romick-Rosendale","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2026010700550926000_11.4.e005932.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103355","article-title":"Predicting lupus membranous nephritis using reduced picolinic acid to tryptophan ratio as a urinary biomarker","volume":"24","author":"Anekthanakul","year":"2021","journal-title":"iScience"},{"key":"2026010700550926000_11.4.e005932.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02264-2","article-title":"Caution in studying and interpreting the lupus metabolome","volume":"22","author":"Zhang","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026010700550926000_11.4.e005932.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221478"},{"key":"2026010700550926000_11.4.e005932.25","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-000910","article-title":"Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial","volume":"10","author":"Jayne","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2026010700550926000_11.4.e005932.26","unstructured":"AstraZeneca . Saphnelo prescribing information. 2021."},{"key":"2026010700550926000_11.4.e005932.27","doi-asserted-by":"crossref","DOI":"10.1186\/ar2887","article-title":"Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN\u03b1 antibody, in systemic lupus erythematosus","volume":"12 Suppl 1","author":"Yao","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2026010700550926000_11.4.e005932.28","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-007-0082-2"},{"key":"2026010700550926000_11.4.e005932.29","doi-asserted-by":"crossref","DOI":"10.3390\/metabo9050101","article-title":"A Comprehensive Plasma Metabolomics Dataset for a Cohort of Mouse Knockouts within the International Mouse Phenotyping Consortium","volume":"9","author":"Barupal","year":"2019","journal-title":"Metabolites"},{"key":"2026010700550926000_11.4.e005932.30","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12040229","article-title":"Indoxyl Sulfate, a Uremic Endotheliotoxin","volume":"12","author":"Lano","year":"2020","journal-title":"Toxins (Basel)"},{"key":"2026010700550926000_11.4.e005932.31","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaa802","article-title":"Stable gene expression for normalisation and single-sample scoring","volume":"48","author":"Bhuva","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026010700550926000_11.4.e005932.32","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262"},{"key":"2026010700550926000_11.4.e005932.33","article-title":"An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"2026010700550926000_11.4.e005932.34","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12110684","article-title":"Indoxyl Sulfate, a Tubular Toxin, Contributes to the Development of Chronic Kidney Disease","volume":"12","author":"Cheng","year":"2020","journal-title":"Toxins (Basel)"},{"key":"2026010700550926000_11.4.e005932.35","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-9-1"},{"key":"2026010700550926000_11.4.e005932.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225445"},{"key":"2026010700550926000_11.4.e005932.37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.41518","article-title":"Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus","volume":"73","author":"Casey","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026010700550926000_11.4.e005932.38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-60563-9","article-title":"Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus","volume":"10","author":"Smith","year":"2020","journal-title":"Sci Rep"},{"key":"2026010700550926000_11.4.e005932.39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/nep.12580","article-title":"Indoxyl sulphate and kidney disease: Causes, consequences and interventions","volume":"21","author":"Ellis","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"2026010700550926000_11.4.e005932.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-017-0457-1","article-title":"Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease","volume":"18","author":"Kami\u0144ski","year":"2017","journal-title":"BMC Nephrol"},{"key":"2026010700550926000_11.4.e005932.41","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/acr.22762","article-title":"Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults","volume":"68","author":"Brunner","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026010700550926000_11.4.e005932.42","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12351"},{"key":"2026010700550926000_11.4.e005932.43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00441-021-03499-4","article-title":"Kidney organoid systems for studies of immune-mediated kidney diseases: challenges and opportunities","volume":"385","author":"Stein","year":"2021","journal-title":"Cell Tissue Res"},{"key":"2026010700550926000_11.4.e005932.44","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16086"},{"key":"2026010700550926000_11.4.e005932.45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00410","article-title":"The Protective Role of Type I Interferons in the Gastrointestinal Tract","volume":"8","author":"Kotredes","year":"2017","journal-title":"Front Immunol"},{"key":"2026010700550926000_11.4.e005932.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.021"},{"key":"2026010700550926000_11.4.e005932.47","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2010.113"},{"key":"2026010700550926000_11.4.e005932.48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214379"},{"key":"2026010700550926000_11.4.e005932.49","doi-asserted-by":"crossref","first-page":"110243","DOI":"10.1016\/j.clim.2024.110243","article-title":"Integration of multi-omics analysis reveals metabolic alterations of B lymphocytes in systemic lupus erythematosus","volume":"264","author":"Iperi","year":"2024","journal-title":"Clin Immunol"},{"key":"2026010700550926000_11.4.e005932.50","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-015-0772-0"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:55:29Z","timestamp":1767776129000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,5]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-005932"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005932","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}